Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma - PubMed
3 hours ago
- #LBCL
- #BiTE
- #CAR T-cell failure
- No standard care exists for LBCL after CAR T-cell therapy failure.
- BiTEs are effective for relapsed/refractory LBCL with pooled ORR of 51% and CR of 31%.
- Pooled PFS and OS rates are 31% and 48%, respectively, with low non-relapse mortality (4%).
- Comparative assessment across BiTE products is not possible with current data.
- Future prospective head-to-head RCTs are needed for definitive comparisons.